Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5752855 | 1.00 | ERBB2 (0.72) | ERBB2MINK1 | |
| SCHEMBL22398055 | 0.91 | ERBB2 (0.71) | ERBB2MINK1 | |
| SCHEMBL5752039 | 0.91 | ERBB2 (0.71) | ERBB2MINK1 | |
| SCHEMBL5752043 | 0.91 | ERBB2 (0.71) | ERBB2MINK1 | |
| SCHEMBL22398057 | 0.91 | ERBB2 (0.71) | ERBB2MINK1 | |
| SCHEMBL24112037 | 0.91 | ERBB2 (0.71) | ERBB2MINK1 | |
| Hydrochloric Acid SCHEMBL22397982 | 0.90 | ERBB2 (0.70) | ERBB2MINK1 | |
| Hydrochloric Acid SCHEMBL22397984 | 0.90 | ERBB2 (0.70) | ERBB2MINK1 | |
| SCHEMBL22398246 | 0.90 | ERBB2 (0.69) | ERBB2MINK1 | |
| SCHEMBL22398041 | 0.90 | ERBB2 (0.69) | ERBB2MINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984653-B2 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-10 | — | — | US | disclosed |
| US-20040242659-A1 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1439178-A1 | HETEROCYCLIC COMPOUNDS, OXAZOLE DERIVATIVES, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242659-A1 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | ABL1, JAK1, BTK | ERBB2 17/4885MINK1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.